https://www.epo.org/en/boards-of-appeal/decisions/t192149eu1
T 2149/19 (Dabigatran etexilate/KRKA) of 25.06.2021
dabigatran etexilate25 06214919krka
https://www.medicines.org.uk/emc/product/100715/smpc
Dabigatran Etexilate 110 mg hard capsule - Summary of Product Characteristics (SmPC) - (emc) |...
Dabigatran Etexilate 110 mg hard capsule - Summary of Product Characteristics (SmPC) by Glenmark Pharmaceuticals Europe Ltd
dabigatran etexilatehard capsule
https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.998751/full
Frontiers | Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with...
We aimed to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model from healthy Chinese subjects and real-world nonvalvular atrial fibrillation (NVAF)...
dabigatran etexilatein chinesefrontierspopulationpharmacokinetic
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ascend-laboratories-llc-issues-voluntary-nationwide-recall-dabigatran-etexilate-capsules-usp-75-mg
Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP...
Parsippany. New Jersey. Ascend Laboratories LLC. is voluntarily recalling Dabigatran Etcxilate Capsules. USP 75 mg and 150 mg to the consumer/user level due to...